Impact of Hcv Status on Healthcare Utilization for Opioid Related Harms Among Patients Receiving Opioid Agonist Therapy
Paige Guyatt(McMaster University), Brittany B. Dennis(McMaster University), Glenda Babe(McMaster University), Jeffrey H. Samet(Boston Medical Center), M. Constantine Samaan(McMaster Children's Hospital), Victoria Weaver(British Royal University), Tea Rosic(Children's Hospital of Eastern Ontario), Aijaz Ahmed(Stanford University), Claire de Oliveira(Centre for Addiction and Mental Health), Joanna C. Dionne(Impact), DH Kim(Stanford University), Paxton Bach(University of British Columbia), Lehana Thabane(St. Joseph’s Healthcare Hamilton), Myanca Rodrigues(McMaster University)
Cited by 1
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine
|Intensive Care Medicine|2020|279
Characterization of Environmental Sources of the Human and Animal Pathogen <i>Cryptococcus gattii</i> in British Columbia, Canada, and the Pacific Northwest of the United States
|Applied and Environmental Microbiology|2006|238
Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients
|JAMA|2021|227
Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A cross-sectional study in a municipal hospital clinic
|The American Journal of Medicine|1992|225